MedTrace Logo

Levetiracetam Treatment of Tardive Dyskinesia

NCT00291213 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-06-06

No results posted yet for this study

Summary

This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.

Conditions

  • Tardive Dyskinesia

Interventions

DRUG

levetiracetam

DRUG

placebo

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Yale University

    lead OTHER

Principal Investigators

  • Scott W Woods, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2006-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00291213 on ClinicalTrials.gov